KILITCH.NSライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (8 5月 2024 @ 13:49):

Stats
本日の出来高	2 074.00
平均出来高	9 674.00
時価総額	5.47B
EPS	INR0 ( 2024-02-08 )
次の収益日	( INR0 ) 2024-05-27
Last Dividend	INR0.500 ( 2019-09-20 )
Next Dividend	INR0 ( N/A )
P/E	36.88
ATR14	INR1.399 (0.41%)

ボリューム相関

長: 0.06 (neutral)

短: 0.26 (neutral)

Signal:(47.222) Neutral

Kilitch Drugs (India) 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Kilitch Drugs (India) 相関 - 通貨/商品

-0.40
( neutral )

-0.47
( neutral )

0.26
( neutral )

-0.78
( moderate negative )

0.02
( neutral )

-0.45
( neutral )

Kilitch Drugs (India) 財務諸表

Annual	2022
収益:	INR1.40B
総利益:	INR648.40M (46.45 %)
EPS:	INR6.71

FY	2022
収益:	INR1.40B
総利益:	INR648.40M (46.45 %)
EPS:	INR6.71

FY	2022
収益:	INR1.14B
総利益:	INR488.01M (42.72 %)
EPS:	INR4.73

FY	2021
収益:	INR685.23M
総利益:	INR312.16M (45.56 %)
EPS:	INR2.37

Financial Reports:

No articles found.

Kilitch Drugs (India) Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)

Kilitch Drugs (India) Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 3.63 - low (20.78%) | Divividend Growth Potential Score: 2.35 - No dividend growth expected in the near future

Information

First Dividend	INR1.000	2010-10-14
Last Dividend	INR0.500	2019-09-20
Next Dividend	INR0	N/A
Payout Date	2019-10-30
Next Payout Date	N/A
# dividends	5	--
Total Paid Out	INR33.00	--
Avg. Dividend % Per Year	0.00%	--
Score	1.15	--
Div. Sustainability Score	3.63
Div.Growth Potential Score	2.35
Div. Directional Score	2.99	--

Next Divdend (Est)
(2025-09-01)

INR0 Estimate 0.00 %

Dividend Stability

0.02 Very Bad

Dividend Score

1.15

Pay Frequency

Sporadic

Yearly Payout

Year	Amount	Yield
2010	INR0	0.00%
2011	INR0	0.00%
2012	INR0	0.00%
2013	INR0	0.00%
2014	INR0	0.00%
2015	INR0	0.00%
2016	INR0	0.00%
2017	INR0	0.00%
2018	INR0.500	0.59%
2019	INR0.500	0.31%
2020	INR0	0.00%
2021	INR0	0.00%
2022	INR0	0.00%
2023	INR0	0.00%
2024	INR0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
RAMCOIND.NS	Dividend Junior	2023-08-02	Annually	23	0.32%
KOKUYOCMLN.NS	Dividend Junior	2023-07-20	Sporadic	16	0.16%
EQUITASBNK.NS	Dividend Junior	2023-07-27	Insufficient data to determine frequency	2	0.56%
ALKEM.NS	Dividend Junior	2023-08-09	Semi-Annually	9	0.71%
SWARAJENG.NS	Dividend Knight	2023-07-06	Annually	23	2.81%
NELCO.NS	Dividend Junior	2023-06-06	Sporadic	22	0.24%
ICIL.NS	Dividend Junior	2023-08-11	Annually	10	0.77%
CENTURYPLY.NS	Dividend Junior	2023-09-20	Annually	19	0.20%
RUPA.NS	Dividend Junior	2023-08-01	Annually	13	0.60%
LODHA.NS	Dividend Junior	2023-09-07	Insufficient data to determine frequency	2	0.06%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0940	1.500	8.12	10.00	[0 - 0.5]
returnOnAssetsTTM	0	1.200	0	0	[0 - 0.3]
returnOnEquityTTM	0.0916	1.500	-0.0933	-0.140	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	0	0.800	-5.00	-4.00	[1 - 3]
quickRatioTTM	0	0.800	-4.71	-3.76	[0.8 - 2.5]
cashRatioTTM	0	1.500	-1.111	-1.667	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	4.20	1.000	9.56	9.56	[3 - 30]
operatingCashFlowPerShareTTM	4.15	2.00	8.62	10.00	[0 - 30]
freeCashFlowPerShareTTM	4.15	2.00	7.93	10.00	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.486	1.000	5.24	5.24	[0.2 - 0.8]
operatingProfitMarginTTM	0.158	1.000	8.85	8.85	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				3.63

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	38.10	1.000	6.25	0	[1 - 100]
returnOnEquityTTM	0.0916	2.50	-0.0600	-0.140	[0.1 - 1.5]
freeCashFlowPerShareTTM	4.15	2.00	8.62	10.00	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	4.15	2.00	8.62	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.383	1.500	-0.783	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0430	1.000	-1.424	0	[0.1 - 0.5]
Total Score				2.35

Kilitch Drugs (India)

Kilitch Drugs (India) Limited engages in the development and operation of pharmaceutical business in India. The company offers parenteral and nasal products, including gastroenterology, anti-inflammatory, anticonvulsant/antiepileptic, anti-malarial, aminoglycoside, antibacterial, anti-hypertensive, anti-infective, diagnostic, sympathomimetic, local anesthetic, neurotonic, uterine stimulant, external preparation, non-steroidal anti-inflammatory, oncology, ophthalmic, and other drugs, as well as vaccines and veterinary products in the form of ampoules, vials, and dry powder injectables. Its parenteral and nasal products also include iron supplements for the treatment of anemia; and metered nasal drops, as well as Klavmox and Onecef products. The company also provides a range of oral formulations, including tablets, capsules, dry syrups, gripe water, and oral powders and liquids in the antibiotic, anti-diabetics, cardiovascular, and other areas. In addition, it offers effervescent tablets and powders, such as ROIPAR, DUREGRA, ROIVIT, and PH-7; and various nutritional products, such as CELTINE. Further, the company provides C-Seal, a topical skin adhesive to hold closely approximated skin edges without marks of sutures and incisions. Additionally, it offers cosmetics and herbal products consisting of a range of oils, lotions, liquids, creams, and paste in skin, personal, and hair care categories, as well as herbal products used in sore throat and prostate problems; and as a supplement for diabetes, obesity, libido, and other conditions. The company also exports its products. Kilitch Drugs (India) Limited was founded in 1978 and is headquartered in Mumbai, India.